After FDA's delayed hold for multiple myeloma drug, Molecular Templates is back in action

It took the FDA 500 days to impose a partial clinical hold on Molecular Template’s clinical trial for a CD38-directed cancer candidate but just 55 to lift it. Molecular Templates revealed Thursday morning that the hold on the phase 1 MT-0169 trial for patients with multiple myeloma has been lifted. The FDA pushed pause on the study in early April, 500 days after the company itself disclosed the second of two cardiac adverse events in patients who had received the therapy. In the intervening time, Molecular Templates dialed down the dose and continued with the trial.